^
over1year
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Keytruda (pembrolizumab) • Q901
over1year
Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor (AACR 2023)
The non-clinical data demonstrate that Q901 not only has a potential as a single agent,but can also be used in combination with other therapeutic strategies to develop next-generation cancer therapeutics to potentially address unmet medical needs.
Clinical • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
ER (Estrogen receptor) • BRCA (Breast cancer early onset)
|
ER positive • HR positive • BRCA wild-type
|
Q901
2years
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=70, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Q901
over2years
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Q901